Previous Close | 1.3400 |
Open | 1.3400 |
Bid | 1.3000 x 1000 |
Ask | 1.4300 x 20100 |
Day's Range | 1.3001 - 1.3500 |
52 Week Range | 0.7000 - 2.0500 |
Volume | 49,989 |
Avg. Volume | 124,057 |
Market Cap | 22.689M |
Beta | 4.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.50 |
Invictus MD Strategies Corp. Opens the Market
TORONTO , March 20, 2018 /CNW/ - Dan Kriznic , Chairman, CEO, Founder & Director, alongside Gene Simmons , Co-Founder of KISS, and Chief Evangelist Officer, Invictus MD Strategies Corp. (GENE), joined ...
MELBOURNE, Australia, March 16, 2018-- Genetic Technologies Limited, a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today the ...
NASDAQ: GENE) to accelerate the prediction of cancer for millions of individuals worldwide. GTG, whose lead product is BREVAGenplus® - a clinically validated risk assessment test for non-hereditary breast cancer - is at the forefront of preventive medicine.
MELBOURNE, Australia, March 06, 2018-- Genetic Technologies Limited a diversified molecular diagnostics company; provider of BREVAGen plus ®, a first-in-class, clinically validated risk assessment test ...
MELBOURNE, Australia, Feb. 15, 2018-- Genetic Technologies Limited a molecular diagnostics company and provider of BREVAGen plus ®, a first-in-class, clinically validated risk assessment test for sporadic ...
MELBOURNE, Australia, Feb. 12, 2018-- Genetic Technologies Limited, wishes to advise that the Company is presently in discussions with the ASX regarding the possible application of ASX Listing Rule 11.1; ...
MELBOURNE, Australia, Feb. 06, 2018-- Genetic Technologies Limited, advises that the Board and Mr Eutillio Buccilli have today agreed that Mr Buccilli step down as Chief Executive Officer with immediate ...
MELBOURNE, Australia, Feb. 05, 2018-- Genetic Technologies Limited, is pleased to announce that the Board of Directors has appointed Dr Paul A. Kasian as Chairman. This follows previous Chairman Dr Malcolm. ...
MELBOURNE, Australia, Jan. 31, 2018--. Genetic Technologies Limited advises that a General Meeting of shareholders that had been requisitioned pursuant to section 249 D of the Corporations Act was held ...
MELBOURNE, Australia, Jan. 30, 2018-- Genetic Technologies Limited, advises that Dr Malcolm R. Brandon and Mr Grahame Leonard, AM have resigned as directors of the Company with effect from 29 January, ...
Completed a three month promotional campaign leading up to and throughout October Breast Cancer Awareness Month Ohio State University: patient recruitment for the collaborative clinical research study ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Helios and Matheson Analytics Inc (NASDAQ: HMNY ) ...
NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Shares of Tetraphase Pharma and Genetic Technologies both climbed higher on Wednesday. Despite any news to serve as a catalyst for the gains, shares of Genetic ...
Research Desk Line-up: Enzymotec Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Genetic ...
Genetic Technologies Limited , a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for non-hereditary ...
Genetic Technologies Limited , a molecular diagnostics company specialising in cancer genomics, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for non-hereditary ...
Genetic Technologies Limited
Genetic Technologies Limited , today announced that on 20 July 2017, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the Company that ...